Foundation Medicine
Mobile Phlebotomy

Convenient Service With No Added Cost
We know on-site blood draws may not be possible for all hospitals and practices. To remove this barrier, Foundation Medicine is pleased to offer in-home blood draws with mobile phlebotomy through our partner, ExamOne®, to support broader access to our FoundationOne®Liquid CDx and FoundationOne®Heme tests.

Physicians or patients can request a remote blood draw for multiple reasons such as:

- Patient is more comfortable in the privacy of their own home
- Patient lives near an ExamOne® service center
- Patient is not feeling well enough to travel
- Patient lives far from the hospital
- No on-site phlebotomy at your practice

Steps for Mobile Phlebotomy:

1. Select “Mobile Phlebotomy Requested” on the completed test requisition form.
2. Your patient will be contacted by our Client Services team to schedule an appointment with our phlebotomy partner, ExamOne®.
3. A licensed phlebotomist will perform the blood draw and overnight the sample to our lab.
4. Patient test results are available typically within two weeks after we receive the sample.

Foundation Medicine offers remote blood draws in every zip code of the United States, including Alaska, Hawaii and Puerto Rico, through a partnership with ExamOne®, which has over 6,000 licensed phlebotomists who can perform blood draws at the patient’s home, apartment, nursing facility, workplace or at one of the 200 ExamOne® service centers around the country. Our Client Services team can assist to identify the nearest location to you or your patient.

TO LEARN MORE:
Visit www.foundationmedicine.com

TO ORDER:
Order online at home.foundationmedicine.com/login

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test please see the Technical Specifications at http://foundationoneheme.com/.

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.